We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+8.99%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21.9B
AUM Growth
+$21.9B
(+100,205%)
Cap. Flow
-$417M
Cap. Flow
% of AUM
-1.9%
Top 10 Holdings %
Top 10 Hldgs %
13.08%
Holding
3,337
New
135
Increased
1,103
Reduced
1,007
Closed
163
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$89.3M |
| 2 |
Keysight
KEYS
|
+$86M |
| 3 |
Nike
NKE
|
+$78.3M |
| 4 |
Amphenol
APH
|
+$76.5M |
| 5 |
Comcast
CMCSA
|
+$72.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Celanese
CE
|
+$108M |
| 2 |
Monster Beverage
MNST
|
+$97.8M |
| 3 |
Starbucks
SBUX
|
+$79.7M |
| 4 |
Texas Instruments
TXN
|
+$67.3M |
| 5 |
Centene
CNC
|
+$64.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.83% |
| 2 | Financials | 13.42% |
| 3 | Healthcare | 13.25% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 7.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Bio-Techne
TECH
$11.2B
| $138K | ﹤0.01% |
2,524
+424
| +20% | +$22.2K |
|
1127
Ares Capital
ARCC
$13.7B
| $136K | ﹤0.01% |
7,343
+4,077
| +125% | +$75.7K |
|
1128
Everest Group
EG
$15.8B
| $136K | ﹤0.01% |
493
| – | – |
|
|
BPMC
1129
DELISTED
Blueprint Medicines
BPMC
| $134K | ﹤0.01% |
1,684
+79
| +5% | +$5.91K |
|
1130
Trimble
TRMB
$13.6B
| $134K | ﹤0.01% |
3,227
+82
| +3% | +$3.26K |
|
|
INFO
1131
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $134K | ﹤0.01% |
1,791
+131
| +8% | +$9.32K |
|
1132
Commercial Metals
CMC
$7.8B
| $133K | ﹤0.01% |
6,000
| – | – |
|
1133
Vanguard Consumer Staples ETF
VDC
$8.14B
| $133K | ﹤0.01% |
835
+60
| +8% | +$9.42K |
|
1134
iShares MSCI Brazil ETF
EWZ
$9.13B
| $132K | ﹤0.01% |
2,800
-701
| -20% | -$30.7K |
|
1135
Winnebago Industries
WGO
$908M
| $132K | ﹤0.01% |
2,524
-116
| -4% | -$5.42K |
|
1136
State Street SPDR S&P Bank ETF
KBE
$1.66B
| $131K | ﹤0.01% |
2,798
-914
| -25% | -$41.4K |
|
1137
ICICI Bank
IBN
$109B
| $130K | ﹤0.01% |
8,680
+1,893
| +28% | +$25.7K |
|
1138
Matsons
MATX
$6.15B
| $130K | ﹤0.01% |
3,197
+119
| +4% | +$4.54K |
|
1139
RH
RH
$3.36B
| $130K | ﹤0.01% |
612
+50
| +9% | +$9.76K |
|
1140
VanEck Semiconductor ETF
SMH
$63.8B
| $130K | ﹤0.01% |
+1,850
| New | +$121K |
|
1141
XPO
XPO
$24B
| $130K | ﹤0.01% |
4,736
| – | – |
|
|
GAP
1142
The Gap Inc
GAP
$7.28B
| $130K | ﹤0.01% |
7,384
+1,039
| +16% | +$17.7K |
|
|
NVTA
1143
DELISTED
Invitae Corporation
NVTA
| $130K | ﹤0.01% |
8,066
+2,311
| +40% | +$40.9K |
|
|
WBT
1144
DELISTED
Welbilt, Inc.
WBT
| $130K | ﹤0.01% |
8,346
-19,255
| -70% | -$330K |
|
|
RAVN
1145
DELISTED
Raven Industries Inc
RAVN
| $129K | ﹤0.01% |
3,760
+116
| +3% | +$3.96K |
|
1146
American International
AIG
$42.9B
| $127K | ﹤0.01% |
2,487
-548
| -18% | -$29K |
|
1147
Etsy
ETSY
$8.21B
| $127K | ﹤0.01% |
2,875
+2,531
| +736% | +$121K |
|
1148
Schwab Fundamental US Large Company Index ETF
FNDX
$26.8B
| $127K | ﹤0.01% |
8,943
| – | – |
|
1149
Idacorp
IDA
$8.24B
| $127K | ﹤0.01% |
1,191
+11
| +0.9% | +$1.18K |
|
|
MFGP
1150
DELISTED
Micro Focus International plc. American Depositary Shares, each representing One Ordinary Share
MFGP
| $127K | ﹤0.01% |
9,123
-15,247
| -63% | -$211K |
|
Similar funds
SLAM
EWA
MIC
P
OSAM
CB
EIM
Glenmede Trust's Q4 2019 Portfolio in Review
As of Q4 2019, Glenmede Trust held 3,337 positions worth $21.9B, up 100,205% from $21.9M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Glenmede Trust's Q4 2019 filing shows 135 new, 1,103 increased, 1,007 reduced and 163 closed positions. Its largest new stake was Callon Petroleum Company: 285,674 shares worth $13.8M. The largest sale was Celanese, an estimated $108M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
- Glenmede Trust's largest Q4 2019 buy was Callon Petroleum Company: 285,674 shares worth $13.8M.
- Glenmede Trust added most to Bristol-Myers Squibb in Q4 2019, an estimated $89.3M increase.
- Glenmede Trust's biggest Q4 2019 reduction was Celanese, cutting an estimated $108M.
- Glenmede Trust fully exited Celgene Corp in Q4 2019, selling an estimated $122K.
- Glenmede Trust's ten largest holdings make up 13% of its $21.9B portfolio in Q4 2019.
- Glenmede Trust opened 135 new positions and closed 163 in Q4 2019.
- Glenmede Trust's portfolio value rose 100,205% quarter-over-quarter to $21.9B.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.